Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237977 | 0.85 | CYP2A6 (0.33) | — | |
| SCHEMBL12820361 | 0.83 | GRM4 (0.37) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4546569 | 0.75 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL18238078 | 0.75 | — | — | |
| SCHEMBL3788418 | 0.75 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL31587098 | 0.71 | ALDH1A1 (0.55) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL3785195 | 0.71 | KDM4E (0.38) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12589415 | 0.70 | LMNA (0.33) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL12603992 | 0.70 | GRM4 (0.38) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12650345 | 0.70 | GRM4 (0.38) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20120172369-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885ALDH1A1 2151/4885GLA 2221/4885 |
| US-20120172369-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | KDM4E 1503/4885ALDH1A1 781/4885GLA 430/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885ALDH1A1 2151/4885GLA 2221/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885ALDH1A1 2151/4885GLA 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.